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Arnaoutakis et al Cardiothoracic Transplantationexamine the PRA level immediately before OHT to exam-
ine the immunologic status of the recipient just before im-
plantation of the allograft, regardless of prior therapies or
PRA levels. It is also impossible to ascertain if a crossmatch
was performed retrospectively or prospectively. Further-
more, information on ‘‘virtual’’ crossmatching is not coded
in the UNOS database, although this technique is increas-
ingly being used and may enhance donor–recipient match-
ing in the future. Although these data suggest that high PRA
does not influence short-term survival, additional informa-
tion regarding treatment algorithms and crossmatch prac-
tices are needed to definitively support a more liberal
strategy for patients bridged to transplant with high PRA
activity.
This study has a relatively short follow-up period. We
chose to begin the study in 2004, because before that time
there were few HMII or XVE recipients bridged to trans-
plant in the UNOS registry. Because sensitization may in-
fluence chronic rejection, additional follow-up is
warranted to determine whether high PRA levels affect
longer-term outcomes, such as 5-year survival.CONCLUSIONS
This is the largest modern study to examine the impact of
detailed PRA information in patients bridged to OHT with
an LVAD. High PRA levels do not affect drug-treated rejec-
tion episodes in the first year post-OHT; however, there is an
associated higher rate of PGD, regardless of device type.
Highly sensitized patients bridged to transplant experience
excellent short-term survival outcomes after OHT.T
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Dr Carmelo Milano (Durham, NC). Dr Shah and colleagues
from Johns Hopkins ought to be commended for their effort to
use the UNOS database. A large number of resources are required
to maintain the UNOS database. These data have not been exten-
sively analyzed. But recently, Dr Shah and colleagues have pub-
lished several reviews of these data that have provided us with
useful clinical knowledge.
The current study shows that heart transplant recipients who un-
derwent LVAD bridging experienced equivalent posttransplant
survival outcomes regardless of device type and PRA status; how-
ever, the high PRA group experienced a longer wait-list time rel-
ative to the low PRA or zero PRA group. This observation is
important and indicates the importance of the pretransplant
LVAD support period. I have one slide that I wanted to show.
This slide illustrates survival outcomes from a recent bridged to
transplant LVAD device trial. This experimental device was im-
planted in approximately 140 patients, and the outcomes over
the course of 1 year are demonstrated. It is important to note
that less than 30% of the patients actually go on to receive a trans-
plant during the first year of support. So when we talk about bridg-
ing patients to transplant, it is a long bridge, with less than 30% of
patients receiving a transplant during the first year.
Furthermore, it is notable that the mortality during device sup-
port is less than 5% in this study, which is actually comparable todiovascular Surgery c Volume 142, Number 5 1243
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Xsurvival after transplant. Therefore, the prolonged wait-list time
may no longer mean that overall survival is reduced for patients
with an increased PRA.
My first question is, can the authors display survival outcomes
beginning from the time of the LVAD implantation rather than
from the time of transplant? The cumulative LVAD and transplant
period should be evaluated to determine the impact of factors such
as increased PRA or device type on overall survival. Did these fac-
tors, increased PRA or the device type, affect outcomes when we
look at outcomes beginning from the time of the device implant
rather from the time of transplant?
Dr George. One of the great things about the UNOS database
is that it contains so many variables. One of the limitations is that
the number of variables is finite. Unfortunately, duration of ven-
tricular assist device support is not available. Also, PRA data are
only included for patients who ultimately receive transplants. So
although there are data on patients who are bridged to transplant
who do not ultimately undergo transplantation, we don’t actually
know what their PRA levels are unless they ultimately receive
a transplant. So as you suggest, there is an increased wait-list
time, and we would expect that to correlate with an increased
wait-list mortality. The data are simply not available in the data-
base to evaluate that.
DrMilano.My second question relates to posttransplant infec-
tion outcomes. Patients with high PRA frequently are treated with
different and increased immunosuppressive therapies, for exam-
ple, plasmapheresis, which may increase infection complications
during the posttransplant period. Were the rates of infection differ-
ent between the 2 groups?
Dr George.We anticipated the infection rate to be higher in the
highly sensitized group for that reason. Surprisingly, the infection
rates are the same. As measured by class I, nonsensitized patients
had an infection rate of approximately 33% and highly sensitized
patients had an infection rate of approximately 35%, and the dif-
ference was not significant.
Dr Milano. My third question is, can the authors detect an ef-
fect from the advent of virtual crossmatch technology versus for-
mal prospective crossmatch for high PRA LVAD recipients? As
we transition to this newer technology, does that seem to be having
a positive impact on, for example, wait-list times?
My last question is a more practical, simple question. Many in-
stitutions have these LVAD recipients who are highly sensitized.
These patients present challenges. We know that their period of
LVAD support is prolonged. Given the data that you have pre-
sented, has that changed your management? Have you changed
your management strategies for these difficult patients on the basis
of these data?
DrGeorge. First, in addressing virtual crossmatch data, we cer-
tainly agree that virtual crossmatching is a significant advance in
this science. We think it is very important, and it is what we prac-
tice at our institution. Unfortunately, whether or not patients un-
derwent virtual crossmatching is another variable that is not
available in the database.
In terms of our own practice, it is our practice to use virtual
crossmatching, or at least declare at the outset which HLA types
will simply be unacceptable for a given recipient. We use prospec-
tive crossmatching sparingly, really only for local donors when
time will permit. All of our patients undergo retrospective1244 The Journal of Thoracic and Cardiovascular Surcrossmatching, and all of our sensitized patients receive intrave-
nous immunoglobulin on the way to the operating room. We
then treat them postoperatively with rituximab, and depending
on their crossmatch data, they will get plasmapheresed.
We have always been aggressive about performing transplanta-
tions in sensitized patients, because it has been our sense that these
patients do well, and I think the results of this study really confirm
that practice. So we will continue to be aggressive with highly sen-
sitized patients.
Dr Robert Higgins (Columbus, Ohio). I think the previous
questions were important, but I will ask a slightly different ques-
tion. Did you have any information about prospective crossmatch
in this series as it relates to the whole group, because I think it is
used in many centers before transplant? And the other question
is about prospective management of patients with high PRA,
whether they received additional therapies before transplantation.
I suspect that may be one of the shortcomings of the UNOS data-
base. But a very nice study.
Dr George. In answering your second question, data relating to
desensitization therapies used preoperatively, perioperatively, and
postoperatively are not available in the UNOS database. That is
something we would certainly be interested in looking at, because
it would be interesting to know which treatments are really im-
proving outcomes, and the database in its current form is not
able to answer those questions.
My answer is similar in regard to the prospective crossmatch-
ing. There is a variable in the database about crossmatching, but
there is no designation of prospective versus retrospective. So
there is no way to know which patients were prospectively cross-
matched and how they did in comparison with thosewhowere only
retrospectively crossmatched.
DrR. Duane Davis (Durham, NC). The idea of using a compos-
ite end point that is essentially just the highest of the 2 classes is
probably not appropriate given that although they are not indepen-
dent because of linkage and so forth, it really is closer to an inde-
pendent variable. So that, in fact, if you were 50% class I and 50%
class II, then you really are closer to a 75% PRA. That gets to my
question. Did you do any sensitivity analysis around the differing
levels of PRA, were there differences in adverse outcomes, partic-
ularly at very high levels of PRA?
And then another comment regarding the interpretation of PRA,
which doesn’t mean the same as having a lot of antibody. It means
that you have broad specificities, and it may not be high antibody
titers at all.
My final comment will be just a plea to the thoracic community.
One of the problems you run into with this data set is that we don’t
mandate PRA being collected at the time transplant candidacy is
done. Therefore, we don’t have that data, and we actually can’t
say what is the impact of being sensitized in terms of dying while
waiting for an organ. The only thing we can say is that we have got-
ten good enough that for the majority of patients we are not having
adverse outcomes, at least in the short term.
DrGeorge.Let me begin by echoing your last comment that the
UNOS data set has different tiers of information, the first tier being
mandatory reporting and the other tier being voluntary, and it does
become difficult in analyzing these data sets when we are missing
significant amounts of data in the other tiers. So I do want to echo
that comment.gery c November 2011
Arnaoutakis et al Cardiothoracic TransplantationIn addressing the composite end point question, I appreciate
those comments. There is an approximately 10% incidence of pa-
tients who are either highly sensitized in one class and not sensi-
tized in the other, and we weren’t entirely sure what to do with
those patients. And we didn’t want to completely ignore this issue
and then potentially bias one group or the other, because although
they were nonsensitized in one group, they were highly sensitized
in another. We wanted some way to take that into account. In the
literature we found several articles that used a composite end point
such as we have. But I do accept your criticism that that may not be
the best way to do this.
The second point about the PRA cut point, any PRA cut point
would be somewhat arbitrary in the sense that there are nonsensi-
tized patients, and then there are patients that have some degree of
sensitization. Previous literature has suggested different cut points;
10% and 25% are 2 commonly used numbers in the literature.
In deciding what cut point to use, we wanted to use a high
enough level that we thought the PRA would at least potentially
be significant and potentially have an impact on outcomes, and
at the same time we wanted to keep the number low enough that
we wouldn’t lose the power to detect that difference if such a dif-
ference existed. So we ended up settling on 25%. However, that
said, in our initial analysis and in constructing our models, we
did use PRA as a continuous variable.We also stratified it a number
of different ways and finally as a dichotomous variable, as weThe Journal of Thoracic and Carpresented. We evaluated our models, and the model with the great-
est explanatory power was the one stratified at 25%. But I do again
acknowledge the criticism that this is a somewhat arbitrary cut
point.
Finally, I want to agree with your point that PRA is sort of
a crude measure of sensitization. We recognize that, and we be-
lieve that the future of this science lies in specific anti-HLA anti-
bodies and virtual crossmatching. But for now, PRA is the most
commonly used measure, so we used it in this study.
DrOctavio Pajaro (Phoenix, Ariz). Actually I was just going to
follow up on Dr Davis’s comments. I had similar questions, but
with the transition from cell-based assays to solid-based assays
and the difference in what we report as a PRA. Really, now we
are reporting something that is just the frequency of the allograft
in the UNOS population. So it means something different immu-
nologically than it did in 2004.
My question is, can you estimate how unpure your control group
is, because especially in hearts, unless you list an unacceptable an-
tigen, then there is no PRA reporting, and many centers won’t list
anybody with unacceptable antigens. So those patients will appear
as a zero PRA on the UNOS, but they are doing a virtual
crossmatch.
Dr George. We are limited in this kind of database analysis to
what is reported to the database. Sowe accept that as a limitation of
the study, that people may not be entirely truthful about the data.diovascular Surgery c Volume 142, Number 5 1245
T
X
